scholarly journals Stress-Induced Cardiomyopathy: As a Diagnosis That Is Time Sensitive and Anticipative in Certain Individuals

2018 ◽  
Vol 2018 ◽  
pp. 1-4
Author(s):  
Vishal Dhulipala ◽  
Prema Bezwada ◽  
Rashika Gottimukkula ◽  
Joseph Abboud
Keyword(s):  
Heart Failure ◽  
Acute Coronary Syndrome ◽  
Takotsubo Cardiomyopathy ◽  
Coronary Syndrome ◽  
Treat Heart Failure ◽  
Myocardial Energetics

Stress-induced cardiomyopathy, also known as Takotsubo cardiomyopathy, presents as an acute coronary syndrome. However, the physiology and pathogenesis are different. It is imperative to treat stress-induced cardiomyopathy as an acute coronary syndrome, and once diagnosed, it is imperative to assess and treat heart failure and wait for the impaired myocardial energetics to resolve. At times, the myocardial recuperation is quick that we miss the diagnosis of Takotsubo cardiomyopathy.

scholarly journals Application of Cardiac Troponin in Cardiovascular Diseases Other Than Acute Coronary Syndrome

2017 ◽  
Vol 63 (1) ◽  
pp. 223-235 ◽  
Author(s):  
Kai M Eggers ◽  
Bertil Lindahl
Keyword(s):  
Heart Failure ◽  
Acute Coronary Syndrome ◽  
Takotsubo Cardiomyopathy ◽  
Cardiac Troponin ◽  
High Sensitivity ◽  
Prognostic Information ◽  
Coronary Syndrome ◽  
Prognostic Assessment ◽  
Increased Risk ◽  
Pulmonary Arterial

Abstract BACKGROUND Increased cardiac troponin concentrations in acute coronary syndrome (ACS) identify patients with ongoing cardiomyocyte necrosis who are at increased risk. However, with the use of more precise assays, cardiac troponin increases are commonly noted in other cardiovascular conditions as well. This has generated interest in the use of cardiac troponin for prognostic assessment and clinical management of these patients. In this review, we have summarized the data from studies investigating the implications of cardiac troponin concentrations in various acute and chronic conditions beyond ACS, i.e., heart failure, myocarditis, Takotsubo cardiomyopathy, aortic dissection, supraventricular arrhythmias, valve disease, pulmonary arterial hypertension, stroke, and in the perioperative setting. CONTENT Cardiac troponin concentrations are often detectable and frankly increased in non-ACS conditions, in particular when measured with high-sensitivity (hs) assays. With the exception of myocarditis and Takotsubo cardiomyopathy, cardiac troponin concentrations carry strong prognostic information, mainly with respect to mortality, or incipient and/or worsening heart failure. Studies investigating the prognostic benefit associated with cardiac troponin–guided treatments however, are almost lacking and the potential role of cardiac troponin in the management of non-ACS conditions is not defined. SUMMARY Increased cardiac troponin indicates increased risk for adverse outcome in patients with various cardiovascular conditions beyond ACS. Routine measurement of cardiac troponin concentrations can however, not be generally recommended unless there is a suspicion of ACS. Nonetheless, any finding of an increased cardiac troponin concentration in a patient without ACS should at least prompt the search for possible underlying conditions and these should be managed meticulously according to current guidelines to improve outcome.

A PILOT STUDY: PLASMA GALECTIN-3 LEVEL IN HEART FAILURE PATIENTS

2017 ◽  
pp. 101-106
Author(s):  
Thi Thanh Hien Bui ◽  
Hieu Nhan Dinh ◽  
Anh Tien Hoang
Keyword(s):  
Heart Failure ◽  
Chronic Kidney Disease ◽  
Acute Coronary Syndrome ◽  
Kidney Disease ◽  
Heart Failure Patients ◽  
Coronary Syndrome ◽  
Nyha Classification ◽  
Galectin 3 ◽  
Severe Chronic Kidney Disease ◽  
Esc Guidelines

Background: Despite of considerable advances in its diagnosis and management, heart failure remains an unsettled problem and life threatening. Heart failure with a growing prevalence represents a burden to healthcare system, responsible for deterioration of patient’s daily activities. Galectin-3 is a new cardiac biomarker in prognosis for heart failure. Serum galectin-3 has some relation to heart failure NYHA classification, acute coronary syndrome and clinical outcome. Level of serum galectin-3 give information for prognosis and help risk stratifications in patient with heart failure, so intensive therapeutics can be approached to patients with high risk. Objective: To examine plasma galectin-3 level in hospitalized heart failure patients, investigate the relationship between galectin-3 level with associated diseases, clinical conditions and disease progression in hospital. Methodology: Cross sectional study. Result: 20 patients with severe heart failure as NYHA classification were diagnosed by The ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure (2012) and performed blood test for serum galectin-3 level. Increasing of serum galectin-3 level have seen in all patients, mean value is 36.5 (13.7 – 74.0), especially high level in patient with acute coronary syndrome and patients with severe chronic kidney disease. There are five patients dead. Conclusion: Serum galectin-3 level increase in patients with heart failure and has some relation to NYHA classification, acute coronary syndrome. However, level of serum galectin-3 can be affected by severe chronic kidney disease, more research is needed on this aspect Key words: Serum galectin-3, heart failure, ESC Guidelines, NYHA

scholarly journals Stem Cell Therapy in Acute Coronary Syndrome

2006 ◽  
Vol 4 (1) ◽  
pp. 9-12
Author(s):  
Rajib Rajbhandari
Keyword(s):  
Heart Failure ◽  
Congestive Heart Failure ◽  
Acute Coronary Syndrome ◽  
Stem Cell ◽  
Cell Therapy ◽  
Stem Cell Therapy ◽  
Cardiovascular Medicine ◽  
Coronary Syndrome

Acule coronary syndrome and congestive heart failure are still among challenging problems in the field of cardiovascular medicine despite many advances in the field. Stem cell therapy has come as a new hope and a promise for the hopeless.

scholarly journals The Evolving Phenotypes of Cardiovascular Disease during COVID-19 Pandemic

2021 ◽  
Author(s):  
Michele Correale ◽  
Francesca Croella ◽  
Alessandra Leopizzi ◽  
Pietro Mazzeo ◽  
Lucia Tricarico ◽  
...  
Keyword(s):  
Heart Failure ◽  
Cardiovascular Disease ◽  
Acute Coronary Syndrome ◽  
New World ◽  
Therapeutic Options ◽  
Atrial Arrhythmias ◽  
Heart Failure Patients ◽  
Coronary Syndrome ◽  
Cardiovascular Patients

AbstractCOVID-19 pandemic has negatively impacted the management of patients with acute and chronic cardiovascular disease: acute coronary syndrome patients were often not timely reperfused, heart failure patients not adequately followed up and titrated, atrial arrhythmias not efficaciously treated and became chronic. New phenotypes of cardiovascular patients were more and more frequent during COVID-19 pandemic and are expected to be even more frequent in the next future in the new world shaped by the pandemic. We therefore aimed to briefly summarize the main changes in the phenotype of cardiovascular patients in the COVID-19 era, focusing on new clinical challenges and possible therapeutic options.

scholarly journals Post-systolic shortening predicts heart failure following acute coronary syndrome

2019 ◽  
Vol 276 ◽  
pp. 191-197 ◽  
Author(s):  
Philip Brainin ◽  
Kristoffer Grundtvig Skaarup ◽  
Allan Zeeberg Iversen ◽  
Peter Godsk Jørgensen ◽  
Elke Platz ◽  
...  
Keyword(s):  
Heart Failure ◽  
Acute Coronary Syndrome ◽  
Coronary Syndrome

scholarly journals The role of levosimendan in acute heart failure complicating acute coronary syndrome: A review and expert consensus opinion

2016 ◽  
Vol 218 ◽  
pp. 150-157 ◽  
Author(s):  
Markku S. Nieminen ◽  
Michael Buerke ◽  
Alain Cohen-Solál ◽  
Susana Costa ◽  
István Édes ◽  
...  
Keyword(s):  
Heart Failure ◽  
Acute Coronary Syndrome ◽  
Acute Heart Failure ◽  
Expert Consensus ◽  
Coronary Syndrome ◽  
Consensus Opinion
Sign in / Sign up

Export Citation Format

Share Document